NCT06607991 is a Phase 1 clinical trial of Blinatumomab Treatment in CNI-resistant Steriod Resistant Nephrotic Syndrome, sponsored by The Children's Hospital of Zhejiang University School of Medicine.

Who is sponsoring NCT06607991?

NCT06607991 is sponsored by The Children's Hospital of Zhejiang University School of Medicine.

What drugs are being tested in NCT06607991?

Interventions in NCT06607991: Blinatumomab Treatment.

What condition does NCT06607991 study?

NCT06607991 studies CNI-resistant Steriod Resistant Nephrotic Syndrome, CNI-intolerent, Steriod Resistant Nephrotic Syndrome, Multidrug Resistant Nephrotic Syndrome.

Is NCT06607991 still recruiting?

NCT06607991 is currently recruiting now. Last updated 6 August 2025.

Last reviewed 2025-08-06 · How we verify

NCT06607991

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Blinatumomab for CNI-Resistant/Intolerant SRNS in Children

Recruiting now Phase 1 Last updated 6 August 2025

What this trial tests

Phase 1 trial testing Blinatumomab Treatment in CNI-resistant Steriod Resistant Nephrotic Syndrome in 6 participants. Currently enrolling.

Timeline

19 September 2024

Primary endpoint
19 September 2026

18 September 2027

Quick facts

Lead sponsor	The Children's Hospital of Zhejiang University School of Medicine
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	19 September 2024
Primary completion	19 September 2026
Estimated completion	18 September 2027
Sites	1 location across China

Drugs / interventions tested

Blinatumomab Treatment — full drug profile →

Conditions studied

CNI-resistant Steriod Resistant Nephrotic Syndrome — all drugs for CNI-resistant Steriod Resistant Nephrotic Syndrome →
CNI-intolerent — all drugs for CNI-intolerent →
Steriod Resistant Nephrotic Syndrome — all drugs for Steriod Resistant Nephrotic Syndrome →
Multidrug Resistant Nephrotic Syndrome — all drugs for Multidrug Resistant Nephrotic Syndrome →

Sponsor

The Children's Hospital of Zhejiang University School of Medicine

Who can join

Adults 2 to 17, any sex, with CNI-resistant Steriod Resistant Nephrotic Syndrome or CNI-intolerent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This exploratory clinical trial aims to evaluate the efficacy and safety of Blinatumomab in treating children with calcineurin inhibitor (CNI)-resistant or multidrug-resistant steroid-resistant nephrotic syndrome (SRNS). Eligible participants include pediatric patients aged 2 to 17 years who have either failed to respond to adequate CNI therapy or are resistant to at least two classes of immunosuppressants, including CNIs and biologics. A short course of low-dose Blinatumomab will be administered in an open-label, single-arm, self-controlled trial design. The study seeks to determine whether Blinatumomab can reduce proteinuria and induce clinical remission in this difficult-to-treat population, offering a potential new therapeutic option for children with limited response to conventional therapies.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Anti-B Cell Strategy in Nephrotic Syndrome: Beyond Rituximab.
Jin Y, Xie Y, Fu H, Liu F, et al · · 2025 · cited 2× · PMID 41007627 · DOI 10.3390/biomedicines13092063

Verify or expand the search:

Other The Children's Hospital of Zhejiang University School of Medicine trials

Trials by the same sponsor.

NCT07368504 — AI for Newborn Metabolic Screening · NA · not yet recruiting
NCT07499154 — Perioperative Lidocaine for Lung Protection in Infants Undergoing Cardiac Surgery · Phase 4 · not yet recruiting
NCT07490041 — Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refr · EARLY_PHASE1 · recruiting
NCT07496541 — Serum Copeptin as Biomarker for Diagnosis and Classification of Polyuric Primary Monosymptomatic Nocturnal Enuresis · not yet recruiting
NCT07045844 — Effects of Enteral Feeding Regimens on NEC, Mortality, and Neurodevelopment in Very Preterm Infants · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06607991 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Children's Hospital of Zhejiang University School of Medicine
Last refreshed: 6 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06607991.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing